ThermoGenesis Corp  

(Public, NASDAQ:KOOL)   Watch this stock  
Find more results for KOOL
0.910
+0.029 (3.27%)
May 17 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 0.89 - 0.93
52 week 0.61 - 1.43
Open 0.93
Vol / Avg. 617.00/15,485.00
Mkt cap 15.03M
P/E     -
Div/yield     -
EPS -0.13
Shares 16.52M
Beta 1.52
Inst. own 9%
May 14, 2013
Q3 2013 Thermogenesis Earnings Conference Call
May 13, 2013
Q3 2013 Thermogenesis Earnings Release (Tentative)
Mar 20, 2013
Thermogenesis at Roth Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '12) 2012
Net profit margin -11.72% -26.21%
Operating margin -11.62% -28.28%
EBITD margin - -25.10%
Return on average assets -10.90% -21.93%
Return on average equity -13.47% -27.71%
Employees 68 -
Carbon Disclosure Rating - -

Address

2711 Citrus Road
RANCHO CORDOVA, CA 95742
United States - Map
+1-916-8585100 (Phone)
+1-916-8585199 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Discussion Group - Google Finance

Description

ThermoGenesis Corp., designs, develops and commercializes devices and disposable tools for the processing, storage and administration of cell and tissue therapies used in the practice of regenerative medicine. Its products automate the volume reduction and cryopreservation of adult stem cell concentrates from cord blood and bone marrow for use in laboratory and point of care settings. The Company sells its products in approximately 30 countries throughout the world to customers that include private and public cord blood banks, surgeons, hospitals and research institutions. The Company provides products and technologies to enables cell separation, processing and cryopreservation for storage of biological fluids, including umbilical cord blood, peripheral blood and bone marrow in a format. These products and technologies are designed for use in the laboratory, as well as point of care. In Januray 2013, itsold its ThermoLine plasma freezer and thawer product line to Helmer Scientific.

Officers and directors

Craig W. Moore Independent Chairman of the Board
Age: 68
Bio & Compensation  - Reuters
Matthew T. Plavan CPA Chief Executive Officer, Director
Bio & Compensation  - Reuters
Dan T. Bessey Chief Financial Officer
Age: 48
Bio & Compensation  - Reuters
Harold Baker Vice President - Commercial Operations & Marketing
Age: 63
Bio & Compensation  - Reuters
Kevin D. Cooksy Vice President - Corporate Development & Scientific Affairs
Age: 50
Bio & Compensation  - Reuters
Ken Pappa Vice President - Manufacturing and Engineering
Age: 51
Bio & Compensation  - Reuters
David W. Carter Independent Director
Age: 73
Bio & Compensation  - Reuters
Patrick J. McEnany Independent Director
Age: 65
Bio & Compensation  - Reuters
Robin C. Stracey Independent Director
Age: 54
Bio & Compensation  - Reuters